Simultaneous Detection of Oseltamivir- and Amantadine-Resistant Influenza by Oligonucleotide Microarray Visualization

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhang, Yingjie ^a   Liu, Qiqi ^a,b   Wang, Dou ^a   Chen, Suhong ^a   Wang, Shengqi ^a,b  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b CHD Biotechnology (Shenzhen) Limited Company   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; MATRIX PROTEIN; MATRIX PROTEIN 2; OLIGONUCLEOTIDE; OSELTAMIVIR; SIALIDASE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; INFLUENZA; INFLUENZA A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MICROARRAY ANALYSIS; NONHUMAN; PROCESS DEVELOPMENT; THROAT CULTURE; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE;

AMANTADINE; ANTIVIRAL AGENTS; BASE SEQUENCE; COST-BENEFIT ANALYSIS; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSELTAMIVIR; POLYMERASE CHAIN REACTION;

EID: 84874301397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057154     Document Type: Article

References (30)

1. Layne SP, Beugelsdijk TJ, Patel CK, Taubenberger JK, Cox NJ, et al. (2001) A global lab against influenza. Science 293: 1729.
2. Lan Y, Zhang Y, Dong L, Wang D, Huang W, et al. (2010) A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Antivir Ther 15: 853-859.
3. Zhou J, Zou L, Zhang X, Liao J, Ni H, et al. (2011) Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009. J Clin Microbiol 49: 2651-2655.
4. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, et al. (2009) Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 15: 552-560.
5. Baz M, Abed Y, McDonald J, Boivin G, (2006) Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43: 1555-1561.
6. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
7. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI, (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
8. Townsend MB, Smagala JA, Dawson ED, Deyde V, Gubareva L, et al. (2008) Detection of adamantane-resistant influenza on a microarray. J Clin Virol 42: 117-123.
9. Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, et al. (2010) Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J Clin Virol 47: 23-28.
10. Redlberger-Fritz M, Aberle SW, Strassl R, Popow-Kraupp T, (2011) Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis. Eur J Clin Microbiol Infect Dis.
11. Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, et al. (2011) Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 203: 13-17.
12. Mazzatti D, Lim FL, O'Hara A, Wood IS, Trayhurn P, (2012) A microarray analysis of the hypoxia-induced modulation of gene expression in human adipocytes. Arch Physiol Biochem.
13. Crameri A, Marfurt J, Mugittu K, Maire N, Regos A, et al. (2007) Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol 45: 3685-3691.
14. Kolquist KA, Schultz RA, Furrow A, Brown TC, Han JY, et al. (2011) Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Cancer Genet 204: 603-628.
15. Chen EC, Miller SA, DeRisi JL, Chiu CY, (2011) Using a pan-viral microarray assay (Virochip) to screen clinical samples for viral pathogens. J Vis Exp.
16. Li L, Qu X, Sun J, Yang M, Song B, et al. (2011) Single-molecule-counting protein microarray assay with nanoliter samples and its application in the dynamic protein expression of living cells. Biosens Bioelectron 26: 3688-3691.
17. Sanvicens N, Pascual N, Fernandez-Arguelles MT, Adrian J, Costa-Fernandez JM, et al. (2011) Quantum dot-based array for sensitive detection of Escherichia coli. Anal Bioanal Chem 399: 2755-2762.
18. Hurt AC, Leang SK, Speers DJ, Barr IG, Maurer-Stroh S, (2012) Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 18: 109-112.
19. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, et al. (2011) Increased detection in Australia and Singapore of a novel influenza A(H1N1) 2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Eurosurveillance 16: 2-7.
20. van der Vries E, Stelma FF, Boucher CA, (2010) Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382.
21. Karthick V, Shanthi V, Rajasekaran R, Ramanathan K, (2012) In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir. Protoplasma.
22. Abed Y, Nehme B, Baz M, Boivin G, (2008) Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 77: 163-166.
23. Richard M, Ferraris O, Erny A, Barthelemy M, Traversier A, et al. (2011) Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 55: 2942-2952.
24. Simon P, Holder BP, Bouhy X, Abed Y, Beauchemin CA, et al. (2011) The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol 49: 715-717.
25. Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, et al. (2012) Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses. PLoS One 7: e31006.
26. Hoopes JD, Driebe EM, Kelley E, Engelthaler DM, Keim PS, et al. (2011) Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 6: e29778.
27. Kim WY, Young Suh G, Huh JW, Kim SH, Kim MJ, et al. (2011) Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 55: 5703-5709.
28. Alonso M, Rodriguez-Sanchez B, Giannella M, Catalan P, Gayoso J, et al. (2011) Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol 50: 114-118.
29. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients- Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58: 893-896.
30. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK, (2010) Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 50: 1252-1255.